Onconova Therapeutics announced that its Chief Medical Officer Mark Gelder, M.D., recently passed away unexpectedly. Michael Saunders, M.D., has been appointed the interim Chief Medical Officer of the Company. "The entire Onconova family is deeply saddened by the loss of our beloved friend and colleague," said Steven M. Fruchtman, M.D., President and Chief Executive Officer of Onconova. "Dr. Gelder dedicated his career to caring for and improving the treatment options available to patients with cancer and his thought leadership and scientific passion will be sorely missed by the oncology community. Mark trained and worked as a gyn oncologist. Because of that experience, he was dedicated to advancing the care of women with reproductive tract cancers. Our goal is to complete the mission Mark started by advancing our trial in endometrial cancer and other cancers as well. We are immensely grateful for his many contributions to Onconova and express our deepest condolences to his family, friends, and colleagues during this difficult time. May he rest in peace."
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ONTX:
- Onconova Therapeutics Announces the Unexpected Passing of Chief Medical Officer Dr. Mark Gelder
- Onconova, Pangea Biomed enter research collaboration
- Onconova Therapeutics and Pangea Biomed Enter into Research Collaboration to Identify Biomarkers of Response to Rigosertib
- Onconova reports FY22 EPS (91c), consensus (93c)
- Onconova Therapeutics Reports Full Year 2022 Financial Results and Provides Business Update